An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions
Thrombocythemia, EssentialPrimary Myelofibrosis
Interventions
DRUG

Bomedemstat

Capsule (oral)

Trial Locations (19)

2025

Middlemore Clinical Trials, Papatoetoe

2050

Royal Prince Alfred Hospital, Camperdown

2065

Royal North Shore Hospital, Saint Leonards

2100

Ospedale di Circolo-a Fondazione Macchi, Varese

4215

Gold Coast Hospital and Health Service, Southport

5000

Royal Adelaide Hospital, Adelaide

15121

Azienda Ospedaliera SS. Antonio, Alessandria

15232

UMPC Hillman Cancer Center, Pittsburgh

27100

Azienda Ospedaliero Universitaria di Bologna, Pavia

33136

University of Miami Leonard M. Miller, Miami

44195

Cleveland Clinic Foundation, Cleveland

45147

Universittsklinikum Essen, Essen

48109

University of Michigan, Ann Arbor

50134

Azienda Ospedaliero-Universitaria Careggi - S.O.D. Ematologia (CRIMM), Florence

98109

Fred Hutchinson Cancer Center, Seattle

Unknown

Queen Mary Hospital, Hong Kong

0622

Waitemata District Health Board, Takapuna

NW1 12G

University College London Hospitals NHS Foundation Trust, London

SE1 9RT

Guy's and Saint Thomas' NHS Foundation Trus, London

All Listed Sponsors
lead

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

NCT05223920 - An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | Biotech Hunter | Biotech Hunter